Denosumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal Osteoporosis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Denosumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Denosumab biosimilar overview

Denosumab biosimilar (HLX-14) is under development for the treatment of giant cell tumor, bone metastases and postmenopausal women with osteoporosis at high risk for fracture. The drug candidate is a humanized monoclonal antibody. It is administered through subcutaneous route. The drug candidate acts by targeting receptor activator of nuclear factor kappa B ligand (RANKL).

Shanghai Henlius Biotech overview

Shanghai Henlius Biotech (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company that develops medicine for oncology, autoimmune and ophthalmic diseases. It offers HANLIKANG, a rituximab injection, which treats non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HERCESSI, trastuzumab for injection for breast, metastatic breast and metastatic gastric cancer; Handayuan, Adalimumab injection, which targets rheumatoid arthritis, Ankylosing spondylitis, Psoriasis, Uveitis, Crohn’s disease and Children Crohn’s disease; Hanbetac, Bevacizumab injection, which treats metastatic Colorectal, recurrent glioblastoma, epithelial ovarian cancer and others and Hans-Shape, Slulizumab injection, for microsatellite high instability (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC). Henlius is headquartered in Shanghai, China.

For a complete picture of Denosumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.